Latest Lamotrigine Stories
HAYWARD, Calif., Jan. 26, 2015 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the U.S.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
Global Epilepsy Market 2014-2018 profiles key players like GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
Lamotrigine Still Retains the Leading Patient Share Among Recently Treated Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
WOODCLIFF LAKE, N.J., Oct. 20, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
MarketOptimizer.org adds “PharmaPoint Epilepsy – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
- VIMPAT® (lacosamide) C-V approved in the U.S. as monotherapy in the treatment of partial-onset seizures in adults with epilepsy(1) BRUSSELS, Sept.
Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store.
LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc.